Although all three UPR sensors provide appealing therapeutic candidates, recently IRE1 activity has been a major focus since elevated levels of IRE1 are associated with poor cancer prognosis (Bartoszewska et al. 2022; Lhomond et al. 2022). The gene discussed is ERN1; the disease is cancer.